Jhonnatan's recent journey with gastric cancer at age 36 ignited a passion within him to share his story and advocate for others. What began as a personal effort to keep…
Editor's Note: Patient Worthy is proud to share this list of resources for those living with stomach cancer. No Stomach for Cancer- This organization has a global reach and specializes…
A newly developed assessment method that brings together a blood-based measurement and a physical body metric is showing promise for forecasting both survival chances and nutritional health in patients battling…
Dewpoint Therapeutics, a U.S.-based biotechnology innovator, has announced the successful closure of its Series D financing round. As reported by thepharmaletter, Dewpoint Therapeutics is renowned for its pioneering work in…
Editor's Note: Patient Worthy is proud to share this story from our friends at No Stomach for Cancer. To see the article in its original form, please click here. In…
Arcus Biosciences and Gilead Sciences issued a press release announcing encouraging overall response rates and six-month progression-free survival rate for their combination treatment of domvanalimab plus zimberelimab and chemotherapy…
November is Gastric Cancer Awareness Month. So what do you know about gastric cancer? Stomach cancer, or gastric cancer, is a cancer that manifests in the stomach lining. It often…
Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…
Historically, it has been challenging to mobilize drug development and research within the rare disease sphere. Given the smaller community sizes, as well as a general lack of profitability,…
If gastric cancer is localized (has not yet spread), it carries a significantly higher 5-year survival rate of 72-75%. But once the cancer spreads, the rate falls lower: 35%…
According to a story from Healio, a phase 3 clinical trial evaluating pembrolizumab plus perioperative chemotherapy as a treatment for locally advanced and resectable gastric adenocarcinoma and gastroesophageal junction cancer…
Throughout the world, it can be difficult to advance research and drug development in the rare disease space. In part, this is because many rare diseases have small population…
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…
What is the underlying cause of cancers such as esophageal adenocarcinoma or intestinal gastric cancer? Are there certain precursor cells that these cancers arise from? According to a news release…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
According to a story from Targeted Oncology, the US Food and Drug Administration has given Orphan Drug designation to ARX788, an experimental therapy. The designation was given for the treatment…
The FDA has recently granted Orphan Drug designation to TST1001, Transcenta Holding Limited's monoclonal antibody for gastric cancer/gastroesophageal junction (GC/GEJ). Prior research has demonstrated TST1001's anti-tumor activity, and ongoing research…
In a news release from early May 2021, biopharmaceutical company Bold Therapeutics ("Bold") shared that its treatment BOLD-100 received Orphan Drug designation for the treatment of patients with gastric…
A team of researchers from the Walter and Eliza Hall Institute of Medical Research (WEHI) in Australia recently made strides in stomach cancer research. While searching for a better understanding…
According to a story from BioSpace, the biopharmaceutical company MacroGenics, Inc. has just announced that the US Food and Drug Administration (FDA) has given Orphan Drug designation to the company's…
According to a publication from EurekAlert, a recent study helmed by the Royal Marsden NHS Foundation Trust suggests that female cancer patients tend to live slightly longer following treatment than…
According to a publication from EurekAlert, a recent study helmed by the Royal Marsden NHS Foundation Trust suggests that female cancer patients tend to live slightly longer following treatment than…
.jpg)
Health News Digest recently published an article that describes a simple blood test called DELFI, meaning DNA evaluation of fragments for early interception. Its simplicity belies the fact that it can detect…
According to a story from Markets Insider, Taiho Oncology, Inc. recently announced that the US Food and Drug Administration (FDA) has officially approved the company's cancer drug LONSURF in the…
PPIs or Proton Pump Inhibitors are one of the top 10 selling generic drugs in the United States. They're used to treat heartburn and acid reflux by suppressing acid production…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
